463 results on '"Rabbitts, Terence H"'
Search Results
52. Progressive 3q Amplification Consistently Targets SOX2 in Preinvasive Squamous Lung Cancer
53. PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces
54. The oncogenic T cell LIM‐protein Lmo2 forms part of a DNA‐binding complex specifically in immature T cells
55. Selection of complementary single-variable domains for building monoclonal antibodies to native proteins
56. The LIM‐only protein Lmo2 is a bridging molecule assembling an erythroid, DNA‐binding complex which includes the TAL1, E47, GATA‐1 and Ldb1/NLI proteins
57. LMO T-cell translocation oncogenes typify genes activated by chromosomal translocations that alter transcription and developmental processes
58. Salmonella-based platform for efficient delivery of functional binding proteins to the cytosol
59. An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes
60. Somatic Mutation in Genes for the Variable Portion of the Immunoglobulin Heavy Chain
61. LMO2 and Gene Therapy for Severe Combined Immunodeficiency
62. Mechanisms of Disease: Activation of the T-Cell Oncogene LMO2 after Gene Therapy for X-Linked Severe Combined Immunodeficiency
63. The hepatitis C virus internal ribosome entry site facilitates efficient protein synthesis in blood vessel endothelium during tumour angiogenesis
64. De novo production of diverse intracellular antibody libraries
65. The oncogenic cysteine-rich LIM domain protein Rbtn2 is essential for erythroid development
66. Single Domain Intracellular Antibodies: A Minimal Fragment For Direct In Vivo Selection of Antigen-specific Intrabodies
67. Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis ofMLLfusion gene leukemia
68. Engineering de novo reciprocal chromosomal translocations associated with Mll to replicate primary events of human cancer
69. Intracellular antibodies and challenges facing their use as therapeutic agents
70. Cloning, purification and structure determination of the HIV integrase-binding domain of lens epithelium-derived growth factor
71. Lipid-mRNA Nanoparticle Designed to Enhance Intracellular Delivery Mediated by Shock Waves
72. Bioluminescence Resonance Energy Transfer 2 (BRET2)‐Based RAS Biosensors to Characterize RAS Inhibitors
73. The promiscuous MLL gene links chromosomal translocations to cellular differentiation and tumour tropism
74. Intracellular antibody capture technology: application to selection of intracellular antibodies recognising the BCR-ABL oncogenic protein
75. Sub-proteome Differential Display: Single Gel Comparison by 2D Electrophoresis and Mass Spectrometry
76. The T Cell Oncogene Tal2 Is Necessary for Normal Development of the Mouse Brain
77. Selection and Characterization of a Nanobody Biosensor of GTP-Bound RHO Activities
78. Correction: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
79. BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
80. Author response: BRET-based RAS biosensors that show a novel small molecule is an inhibitor of RAS-effector protein-protein interactions
81. A chromosomal basis of lymphoid malignancy in man
82. Preventing HIV Infection by Binding LEDGF with an Intracellular Antibody that Mimics HIV Integrase
83. Intracellular immunization against HIV infection with an intracellular antibody that mimics HIV integrase binding to the cellular LEDGF protein
84. Abstract LB-068: From intracellular antibody fragments to small molecule inhibitors of mutant KRAS
85. A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS
86. Extending the repertoire of the mixed-lineage leukemia gene MLL in the leukemogenesis
87. Of methods and mapping
88. Cloning, purification and structure determination of the HIV integrase‐binding domain of lens epithelium‐derived growth factor.
89. Chromosomal Translocations and Genome Rearrangements in Cancer / edited by Janet D. Rowley, Michelle M. Le Beau, Terence H. Rabbitts.
90. Chromosomal Translocations and Genome Rearrangements in Cancer
91. LMO2 at 25 years: a paradigm of chromosomal translocation proteins
92. Cesar Milstein: October 8, 1927-March 24, 2002
93. Functional inhibition of β-catenin-mediatedWnt signaling by intracellular VHHantibodies
94. Isolation of Antigen-Specific Intracellular Antibody Fragments as Single Chain Fv for Use in Mammalian Cells
95. The LMO2 Master Gene; Its Role as a Transcription Regulator Determining Cell Fate in Leukemogenesis and in Hematopoiesis
96. Sequential Gene Targeting to Make Chimeric Tumor Models with De Novo Chromosomal Abnormalities
97. Changing the Subcellular Location of the Oncoprotein Bcr-Abl Using Rationally Designed Capture Motifs
98. Protocol for the selection of single-domain antibody fragments by third generation intracellular antibody capture
99. PCRPi: Presaging Critical Residues in Protein interfaces, a new computational tool to chart hot spots in protein interfaces
100. A Complete Map of the Human Immunoglobulin VH Locus
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.